Daiichi Sankyo And AstraZeneca's Shows Statistically Significant And Clinically Meaningful Improvement In HR+, HER2 Low Breast Cancer: DESTINY-Breast06 Trial Results
Daiichi Sankyo And AstraZeneca's Shows Statistically Significant And Clinically Meaningful Improvement In HR+, HER2 Low Breast Cancer: DESTINY-Breast06 Trial Results
第一三共和阿斯利康的HR+、HER2低乳腺癌显示出统计学上显著且具有临床意义的改善:Destiny-breast06试验结果
- Daiichi Sankyo and AstraZeneca's ENHERTU also demonstrated a clinically meaningful progression-free survival improvement in patients with HER2 ultralow expression
- Plans for global regulatory submissions are underway
- 第一三共和阿斯利康的ENHERTU还显示,HER2超低表达患者的无进展存活率改善具有临床意义
- 全球监管申报计划正在进行中